Name | Prasugrel |
Synonyms | CS 747 Efient Ly640315 Ly 640315 Ly-640315 Prasugrel Unii-34K66tbt99 Prasugrel [INN] [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxo-ethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate 2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7- tetrahydrothieno[3,2-c]pyridin-2-yl acetate Ethanone, 2-(2-(acetyloxy)-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-1-cyclopropyl-2-(2-fluorophenyl)- Ethanone, 2-(2-(acetyloxy)-6,7-dihydrothieno(3,2-C)pyridin-5(4H)-yl)-1-cyclopropyl-2-(2-fluorophenyl)- Acetic acid 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl ester |
CAS | 150322-43-3 |
EINECS | 801-962-1 |
InChI | InChI=1/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3 |
InChIKey | DTGLZDAWLRGWQN-UHFFFAOYSA-N |
Molecular Formula | C20H20FNO3S |
Molar Mass | 373.44 |
Density | 1.347 |
Melting Point | 120.0 to 124.0 °C |
Boling Point | 493.5±45.0 °C(Predicted) |
Flash Point | 252.252°C |
Solubility | Soluble in water (30 mg/ml at 25 °C), DMSO (<1 mg/ml at 25 °C), and ethanol (7 mg/m |
Vapor Presure | 0mmHg at 25°C |
Appearance | White solid |
Color | white to beige |
pKa | 3.65±0.20(Predicted) |
Storage Condition | 2-8°C |
Sensitive | Sensitive to heat |
Refractive Index | 1.619 |
MDL | MFCD09954140 |
Use | An ADP receptor inhibitor |
In vitro study | Prasugrel is a new type of orally active thienopyridine, which has a faster, higher and more reliable platelet aggregation inhibition effect than clopidogrel, indicating that it is metabolized into an active metabolite in the body, it has selective P2Y(12) antagonistic activity. |
In vivo study | Prasugrel exhibited platelet inhibition in WT mice and was 8.2 times more potent than clopidogrel. In a rat model with cerebral and peripheral arterial occlusive disease, Prasugrel (3 and 10 mg/kg) dose-related significant reduction of thrombus-mediated cerebral infarction 24 hours after irradiation. In a rat model of embolic cerebral infarction, Prasugrel (0.3-3 mg/kg) dose-related reduced the incidence, total area and total number of cerebral infarcts 24 hours after vascular injury. In rats with lauric acid-induced peripheral vascular occlusive disease, Prasugrel (0.03-3 mg/kg/day) administered for 11 consecutive days one day before lauric acid injection dose-dependently inhibited the development of the disease. Prasugrel was effective in dogs (0.03-0.3 mg/kg/day) and monkeys (0.1 and 0.3 mg/kg/day) administered once a day for 14 days, dose-related and additive inhibition of ADP-induced platelet aggregation. In a rat model of electrically induced arterial thrombosis, Prasugrel (0.1-1 mg/kg/day, p.o.) significantly prolonged arterial occlusion and increased arterial patency. |
Safety Description | 24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
HS Code | 29349990 |